Table 5. Cost-Effectiveness Results by Gender and Genotype, Triple Therapy with Telaprevir.
| Genotype 1 | Cost (US, $) | QALY | ICER ($/QALY) | |
| Men | FibroTest Rule In | 230,651 | 15.58 | – |
| Liver Biopsy Only | 232,502 | 15.63 | dominated | |
| FibroTest Rule Out | 233,499 | 15.63 | dominated | |
| FibroTest Only | 236,167 | 15.84 | 21,200 | |
| FibroTest and Biopsy | 237,482 | 15.86 | dominated | |
| Immediate Treatment | 240,240 | 15.99 | 27,200 | |
| Women | FibroTest Rule In | 248,603 | 16.69 | – |
| Liver Biopsy Only | 250,611 | 16.74 | dominated | |
| FibroTest Rule Out | 251,762 | 16.73 | dominated | |
| FibroTest Only | 255,660 | 16.96 | 26,100 | |
| FibroTest and Biopsy | 257,002 | 16.98 | dominated | |
| Immediate Treatment | 259,853 | 17.10 | 30,000 |
(ICER: incremental cost-effectiveness ratios. dominated: strategy costs more but achieves less QALY than the previous strategy or a combination of strategies).